Novartis Resolves Pluvicto Drug Shortage Status

Novartis, the Swiss pharmaceutical giant, announced that the U.S. Food and Drug Administration (FDA) has resolved the shortage of Pluvicto, an intravenous radioligand therapy used to treat advanced prostate cancer. The company stated that the availability of the drug will continue to increase until 2024.

Providing Better Access for Patients

Pluvicto has garnered approval in the United States, the European Union, and other countries as a treatment option for adults with advanced prostate cancer who have undergone prior anti-cancer therapies. Novartis has dedicated significant effort to enhance the capacity and reliability of its radioligand therapies' supply to ensure patients can access this much-needed treatment. Additionally, the company aims to cater to future growth as an increasing number of patients may become eligible for this therapy.

Victor Bulto, the president of Novartis U.S., expressed his dedication to this cause, stating, "We have been working hard to increase the capacity and improve the reliability of the supply of our radioligand therapies to ensure patients have access to this therapy and to prepare for future growth as more patients may become eligible for this treatment."

Expanding Production Capacity

Novartis shared that its weekly production capacity has more than doubled since May. As part of its ongoing efforts, the company plans to further expand its production lines at various sites. By doing so, Novartis aims to meet the rising demand for Pluvicto and bolster its commitment to patient well-being.